GS
IBRX icon

GTS Securities’s ImmunityBio IBRX Stock Holding History

GTS Securities’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-19,200
Closed -$103K – 4088
2024
Q1 		$103K Buy
+19,200
New +$86.9K ﹤0.01% 3519

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

GTS Securities's IBRX Position: Q1 2026 in Review

GTS Securities opened a new position in ImmunityBio (IBRX) in Q1 2026: 14,185 shares worth $109K. The stake represents ﹤0.01% of the portfolio and ranks #1420 among its holdings. This is a return to the name: GTS Securities previously reported a position in IBRX as recently as Q1 2024.

GTS Securities first reported a position in IBRX in Q1 2024 and has held it in 2 quarters since. The position peaked at $110K in Q1 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • GTS Securities held 14,185 shares of ImmunityBio worth $109K as of Q1 2026.
  • ImmunityBio was a new GTS Securities position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1420 holding.
  • GTS Securities first reported a position in ImmunityBio in Q1 2024 and has held it in 2 quarters since.
  • GTS Securities's ImmunityBio position peaked at $110K in Q1 2024.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.